OcellO Therapeutics

OcellO is a specialized contract research organization (CRO) providing advanced 3D cell culture-based drug discovery services. The company leverages a proprietary high-content screening platform to analyze the effects of drug candidates on complex, physiologically relevant 3D models such as organoids and patient-derived tissues. Their technology is particularly effective in oncology and polycystic kidney disease, where it quantifies morphological changes and therapeutic efficacy with high precision. By automating the culture and imaging processes, OcellO enables high-throughput screening that bridges the gap between traditional 2D cell assays and animal models. In May 2021, OcellO was acquired by Crown Bioscience, a global drug discovery and development services company. This acquisition integrated OcellO's 3D in vitro expertise into Crown Bioscience's extensive portfolio of translational platforms.